



NDA 50-461/S-139

GlaxoSmithKline
Attention: Debra Hackett
Associate Director, U.S. Regulatory Affairs
One Franklin Plaza
P.O. Box 7929
Philadelphia, PA 19101-7929

Dear Ms. Hackett:

Please refer to your supplemental new drug application dated March 16, 2004, received March 17, 2004, submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Ancef[®] (cefazolin) Injection. We note that this application is subject to the exemption provisions contained in section 125(d)(2) of Title I of the FDA Modernization Act of 1997.

This supplemental new drug application provides for the addition of a *Geriatric Use* subsection in the **PRECAUTIONS** section.

We have completed our review of this supplemental new drug application. It is approved, effective on the date of this letter, for use as recommended in the final printed labeling (FPL) submitted on March 17, 2004.

If a letter communicating important information about this drug product (i.e., a "Dear Health Care Professional" letter) is issued to physicians and others responsible for patient care, we request that you submit a copy of the letter to this NDA and a copy to the following address:

MEDWATCH, HF-2
FDA
5600 Fishers Lane
Rockville, MD 20857

We remind you that you must comply with the requirements for an approved NDA set forth under 21 CFR 314.80 and 314.81.

NDA 50-461/S-139

Page 2

If you have any questions, call LT Raquel Peat, Regulatory Health Project Manager, at (301) 827-2125.

Sincerely,

{See appended electronic signature page}

Janice M. Soreth, M.D.

Director

Division of Anti-Infective Drug Products

Office of Drug Evaluation IV

Center for Drug Evaluation and Research

Enclosure: labeling

**This is a representation of an electronic record that was signed electronically and
this page is the manifestation of the electronic signature.**

/s/

Janice Soreth
6/2/04 12:53:28 PM